Aliment Pharmacol Ther
- AHUJA D, Yeh KH, Patel SB, Park SK, et al
Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705
Patients With Inflammatory Bowel Diseases in Low Incidence Regions-A U.S.
Claims-Based Study.
Aliment Pharmacol Ther. 2026;63:885-887.
- FAYE AS, Axelrad J, Sun J, Halfvarsson J, et al
Treatment-Free Outcomes Following Surgery for IBD: A Nationwide Cohort Study.
Aliment Pharmacol Ther. 2026;63:821-837.
Am J Gastroenterol
- BHAT S, Falaiye T, Moses J, Lukin DJ, et al
The Costs of Inflammatory Bowel Disease and the Financial Impact of Insurance
Delays.
Am J Gastroenterol. 2026 Feb 27. doi: 10.14309/ajg.0000000000003975.
- HARRIS HM, Ghoneim S, Kochar B, Casey K, et al
Differences in Outcomes following Ileocecal Resection in Older Adults with
Crohn's Disease in the Biologic Era.
Am J Gastroenterol. 2026 Feb 25. doi: 10.14309/ajg.0000000000003978.
Clin Gastroenterol Hepatol
- AHUJA D, Yeh KH, Patel SB, Lee HH, et al
Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor
Antagonists in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2026;24:794-804.
Dig Dis Sci
- MAHADEVAN U, Sands BE, Ha C, Yimgang D, et al
Epidemiology and Treatment of Inflammatory Bowel Disease in Pregnancy: Results
from a Retrospective, Observational Study.
Dig Dis Sci. 2026 Feb 25. doi: 10.1007/s10620-026-09725.
- BLACHIER F
Reduced Mitochondrial Oxidative Phosphorylation in Colonic Explants and
Ulcerative Colitis: Dangerous Liaisons.
Dig Dis Sci. 2026 Feb 23. doi: 10.1007/s10620-026-09755.
- DUPENLOUP P, Selnes O, Streett SE, Brandeau ML, et al
Infliximab Monotherapy Versus Infliximab and Azathioprine Combination Therapy in
Patients with Ulcerative Colitis: A Cost-Effectiveness Analysis.
Dig Dis Sci. 2026 Feb 22. doi: 10.1007/s10620-026-09761.
- SONG JH, Seong G, Shin J, Kong SM, et al
Effect of Concomitant Immunomodulator Use by UST-CDST Classification on Clinical
Relapse in Crohn's Disease Patients Treated with Ustekinumab: A Multicenter
Study.
Dig Dis Sci. 2026 Feb 21. doi: 10.1007/s10620-026-09760.
Eur J Gastroenterol Hepatol
- FOTEINOGIANNOPOULOU K, Nikolaou P, Orfanoudaki E, Theodoraki E, et al
The rate and risk factors for malignancy in patients with inflammatory bowel
disease in Crete: a case control study.
Eur J Gastroenterol Hepatol. 2026;38:327-332.
Gastroenterology
- BOURGONJE AR, Mian P
Rethinking Infliximab Dosing in Acute Severe Ulcerative Colitis with
Model-Informed Precision Dosing.
Gastroenterology. 2026 Feb 23:S0016-5085(26)00152.
- BOSSUYT P, Rahier JF, Baert F, Louis E, et al
The effect of dose-intensification after secondary loss of response to
ustekinumab in Crohn's disease: Results of the REScUE study.
Gastroenterology. 2026 Feb 24:S0016-5085(26)00146.
- DUBOIS L, Chaussard A, Seksik P, Nancey S, et al
Uncovering the dynamics of mucosa-associated microbiota in post-operative
recurrence of Crohn's disease.
Gastroenterology. 2026 Feb 24:S0016-5085(26)00147.
Inflamm Bowel Dis
- HARPAZ N, Odze RD
Updated pathologic classification of inflammatory bowel disease-associated
colorectal dysplasia: A guide for clinicians.
Inflamm Bowel Dis. 2026 Feb 27:izag011. doi: 10.1093.
- NAPOLITANO D, Bozzetti M, Vanzi V, Lo Cascio A, et al
Bowel urgency in inflammatory bowel disease: A concept analysis.
Inflamm Bowel Dis. 2026 Feb 25:izag018. doi: 10.1093.
- PAL P, Mateen MA, Sekaran A, Naaz SM, et al
Comparing diagnostic accuracy of transperineal ultrasound using microconvex probe
versus conventional linear probe to predict rectal histoendoscopic activity in
ulcerative colitis: a paired prospective, head-to-head comparative study.
Inflamm Bowel Dis. 2026 Feb 25:izag016. doi: 10.1093.
J Clin Gastroenterol
- FERRANTE M, Christensen B, Bressler B, Brett NR, et al
Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in
Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Expansion
Chart Review Study.
J Clin Gastroenterol. 2026 Feb 24. doi: 10.1097/MCG.0000000000002350.
J Gastroenterol
- WANG X, Tu Y, Zhang S, Che T, et al
Severity of surgical histopathological fibrosis predicted postoperative
recurrence in Crohn's disease: a multi-center retrospective cohort study.
J Gastroenterol. 2026 Feb 26. doi: 10.1007/s00535-026-02374.
Lancet Gastroenterol Hepatol
- OLDENBURG L, Haanappel AEG, Ali M, Bosman C, et al
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective
10-year follow-up of the LIR!C trial.
Lancet Gastroenterol Hepatol. 2026 Feb 19:S2468-1253(25)00374.
PLoS One
- ABOU RACHED A, Saniour J, Geagea A, Salameh C, et al
Updated data on the epidemiology of Inflammatory Bowel Disease (IBD) in Lebanon.
PLoS One. 2026;21:e0340892.
Scand J Gastroenterol
- GUNNARSSON J, Mavroudis G, Agren S, Lasson A, et al
Adalimumab and infliximab are equally efficient in achieving sustained remission
in ulcerative colitis but infliximab is superior in severe disease-a
retrospective observational study.
Scand J Gastroenterol. 2026 Feb 22:1-11. doi: 10.1080/00365521.2026.2633732.
- BOUWKNEGT DG, Donker HC, van Es B, Dijkstra G, et al
Liver enzyme alterations during pregnancy in IBD are not attributable to disease
activity or medication.
Scand J Gastroenterol. 2026;61:317-328.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016